about
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers.The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score.High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis.Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis.Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequencySubspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease.Role of MicroRNAs in Fibrosis.Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement.Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease.Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review.Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases.International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosOutcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis.Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features.Mapping and predicting mortality from systemic sclerosis.The concept of early systemic sclerosis following 2013 ACR\EULAR criteria for the classification of systemic sclerosis.Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group.Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment.EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research.Tissue Doppler imaging in systemic sclerosis: a 3-year longitudinal study.Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role?Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy.N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis.Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study.Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc).Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement.Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.IL-22 capacitates dermal fibroblast responses to TNF in scleroderma.Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis.MiRs in RA: possible biomarkers and therapeutic targetsEarly Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic PositivityEarly Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 LevelsThe β-fibrinogen -455 G>A gene polymorphism is associated with peripheral vascular injury in systemic sclerosis patients[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]
P50
Q33766384-4D6C3DF8-0E7D-4891-B645-875D65F26918Q33796186-5569ABD3-7C45-4503-9163-A3C70A7B2018Q34066564-2F91F958-5548-485C-8300-567DE1FBB02EQ34237586-38C2D083-1F0B-4DC4-B92E-89650C1D545DQ35954658-C0C05112-0463-494D-9570-2AAA8DAA3820Q36060142-396BC23C-52EF-4066-8513-1764DC56457DQ36093326-C9D18F95-FAD0-41CC-A0D8-3BA218BB75BFQ36153763-118B2D7C-AC34-4B55-AD02-B8579400ED10Q36633414-E0EC2749-A70A-41B4-92F7-B8B5ACFD8D40Q36687460-F83BCCFC-928C-42B9-8B27-39A157D2B0C9Q37609999-6EBDEC09-A5AF-4C45-8FA8-2B24F5481068Q37629606-3DEF1037-52C5-43F4-9DAD-4ECF154EB3BFQ38657993-F48D032B-9CCA-4BC3-96B3-9987F7189901Q39762874-EFC6068C-89C0-448A-BD61-266A8211E7B9Q39938323-407DC7FF-D1AD-4D11-BE12-4EFFF24E64C2Q40073055-183215C7-1FB5-40E9-A6AA-4FCEE241EE83Q40183753-A7377A7B-039E-45CB-80D8-31D2B510BCC9Q40301472-E9A0EC5E-E426-4D9A-B730-4C9E3EC0B0FCQ40404296-2760C34D-CF95-4228-B52E-69174DB43BDBQ40469082-7068693A-38DB-46E5-B183-CC2A685E0D53Q41108942-3D2D88D3-2701-41C5-B959-C69514F4FA72Q42983684-458D49CF-4777-4436-A84B-84746E594C13Q45226627-8436B68E-75BE-440F-8A92-8F47304C69C9Q45364555-19A52EAC-468C-411E-B5F6-492B71D920DEQ45715684-B40D1FE5-CF44-4975-B759-9E05222D87A6Q46987453-0710A1E3-6185-4705-B339-D0750FFD3063Q48560986-2D8B3A12-766B-4F0A-9429-44C7B0869DF6Q48617946-C847E29C-10E0-4E46-A74F-757681A42203Q50016508-87946FF2-A622-4225-8DF1-8F9AF0E9CE2EQ51452981-E24A7DF6-ABE9-43A8-B8B5-6ABF0D15FDF8Q51550147-A6607C52-35A6-4DD4-BB88-BBABEB0AF253Q51684920-B36F7337-7D44-46B7-84CB-690BFEB3BA59Q51693090-559A6A0D-700E-414B-898A-1F1F12D8EBFAQ52911127-85C6B2D8-54F9-43C1-8094-13B815AFC2CBQ54511770-AE4A20E7-01D6-45F2-BFC0-8B9417381102Q59616331-AC5BE0D9-87B6-4147-BD5C-5466C9B530BAQ60641609-429DB60A-B218-48A0-8150-70E7550E90A2Q60641610-9C1C8629-F328-4C73-96BB-33DF30556C22Q60641615-CAAEAC3F-977E-4B9C-AA7B-C6C78EDBD1B0Q60641616-6F8DFBAA-49AA-468E-9961-B551556A1578
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Serena Vettori
@ast
Serena Vettori
@en
Serena Vettori
@es
Serena Vettori
@nl
Serena Vettori
@sl
type
label
Serena Vettori
@ast
Serena Vettori
@en
Serena Vettori
@es
Serena Vettori
@nl
Serena Vettori
@sl
prefLabel
Serena Vettori
@ast
Serena Vettori
@en
Serena Vettori
@es
Serena Vettori
@nl
Serena Vettori
@sl
P1053
A-8641-2016
P106
P1153
21935486600
P21
P31
P3829
P496
0000-0001-5617-9829